Skip to main content
    I

    Insmed Inc (INSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $122.88
    +1.72 (+1.42%)

    Market Cap: $26.58B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Insmed Inc (INSM) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Insmed are Ascendis Pharma AS (ASND), Genmab AS (GMAB) and Revolution Medicines (RVMD). By market cap, Insmed ranks 7th of the 13 companies on this page; argenx NV ADR (ARGX) is the largest at $60.37B. The median P/E of the 6 companies with a P/E is 26.4x.

    Peer Comparison

    INSM's ROIC of -44.2% is below the peer median of 4.8%, and its revenue growth of 268.4% is above the median of 14.7%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Insmed (INSM)$26.58BN/A17.7x-39.9%-44.2%268.4%0.00%
    Ascendis Pharma AS (ASND)$18.06BN/A13.5x72.9%12.4%73.0%0.00%
    Genmab AS (GMAB)$31.67B35.8x19.2x17.0%4.8%16.1%0.00%
    Revolution Medicines Inc (RVMD)$37.27BN/A181.6x0.0%-52.1%-95.2%0.00%
    Roivant Sciences Ltd (ROIV)$28.64BN/A679.3x0.0%N/A2136.0%0.00%
    Exelixis Inc (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    Summit Therapeutics PLC (SMMT)$11.32BN/AN/A0.0%N/A-100.0%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Jazz Pharmaceuticals PLC (JAZZ)$15.50B18.4x3.3x4.4%3.5%10.4%0.00%
    BeOne Medicines AG (ONC)$47.58B50.0x18.7x13.9%7.5%33.8%0.00%
    Royalty Pharma Plc (RPRX)$39.85B12.9x11.7x25.7%7.6%13.3%1.37%
    Spyre Therapeutics Inc. (SYRE)$9.88BN/AN/A0.0%N/A0.0%0.00%
    argenx NV ADR (ARGX)$60.37B33.5x6.1x31.7%N/A52.1%0.00%
    Peer median$23.35B26.4x14.7x9.1%4.8%14.7%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Insmed, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Ascendis Pharma AS (ASND)
    Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
    ASND competitors
    Genmab AS (GMAB)
    Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
    GMAB competitors
    Revolution Medicines Inc (RVMD)
    Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted...
    RVMD competitors
    Roivant Sciences Ltd (ROIV)
    Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive...
    ROIV competitors
    Exelixis Inc (EXEL)
    Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development...
    EXEL competitors
    Summit Therapeutics PLC (SMMT)
    Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America...
    SMMT competitors
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    Jazz Pharmaceuticals PLC (JAZZ)
    Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United...
    JAZZ competitors
    BeOne Medicines AG (ONC)
    BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe...
    ONC competitors
    Royalty Pharma Plc (RPRX)
    Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States.
    RPRX competitors
    Spyre Therapeutics Inc. (SYRE)
    Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by...
    SYRE competitors
    argenx NV ADR (ARGX)
    argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases...
    ARGX competitors

    Frequently Asked Questions About INSM

    Who are Insmed's main competitors?

    The companies most similar to Insmed include Ascendis Pharma AS (ASND), Genmab AS (GMAB), Revolution Medicines (RVMD), Roivant Sciences (ROIV) and Exelixis (EXEL), listed from the closest match.

    Who is Insmed's biggest competitor?

    argenx NV ADR (ARGX) is the largest of the similar companies at $60.37B; Ascendis Pharma AS (ASND) is the closest match by business profile, size, sector and industry.

    How does INSM stock compare with its competitors?

    INSM's P/S is 17.7x against a peer median of 14.7x; its net margin is -39.9% against a peer median of 9.1%.

    Which of Insmed's competitors pays a higher dividend?

    Insmed pays no dividend. Royalty Pharma Plc (RPRX) has a higher forward dividend yield; Royalty Pharma Plc (RPRX) has the highest at 1.37%.

    Is Insmed bigger than its competitors?

    No. Insmed is 7th by market cap among the 13 companies on this page; the largest is argenx NV ADR (ARGX) at $60.37B.